Archives

CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

B Validates platform’s ability to rapidly iterate across immune cell types Leverages novel NK and myeloid co-programming architecture to deliver coordinated immune activation Powered by… Login to continue reading Login…

Read MoreCREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

Mozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes

P MTX-101 demonstrated decreases in self-reactive pathogenic T cells, improved β cell viability, and—at higher dose levels—numeric increase of C-peptide production SEATTLE and BRISBANE, Australia, April 23,… Login to continue reading Login…

Read MoreMozart Therapeutics Announces Positive Interim Phase 1 Data in Adults with Stage 3 Type I Diabetes

FERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION

P Novel bispecific antibody with a dual mechanism of action targeting anemia of inflammation in chronic kidney disease, autoimmune disease, and cancer Experienced leadership and… Login to continue reading Login…

Read MoreFERROSA THERAPEUTICS ANNOUNCES SEED FINANCING TO ADVANCE A FIRST-IN-CLASS BISPECIFIC ANTIBODY PROGRAM FOR ANEMIA OF INFLAMMATION

ZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere

B Project-Based Charter School Network Demonstrates Commitment to Safety While Preserving Open, Relationship-Driven Culture PHILADELPHIA, April 23, 2026 /PRNewswire/ — ZeroEyes, creators of the leading AI-powered… Login to continue reading Login…

Read MoreZeroEyes and High Tech High Collaboration Protects Students While Maintaining Open, Collaborative Learning Atmosphere